The biological evaluation of novel antioestrogens for the treatment of breast cancer

Cole, 1980, Major aspects of the epidemiology of breast cancer, Cancer, 46, 865, 10.1002/1097-0142(19800815)46:4+<865::AID-CNCR2820461303>3.0.CO;2-3 Vorherr, 1980 Kelsey, 1979, A review of the epidemiology of human breast cancer, Epidemiol Rev, 1, 74, 10.1093/oxfordjournals.epirev.a036215 Kelsey, 1988, Breast cancer epidemiology, Cancer Res, 48, 5615 Boring, 1991, Cancer Statistics, 1991, CA Cancer J. Clinicians, 41, 19, 10.3322/canjclin.41.1.19 Eppenberger, 1986, 23 Cho-Chung, 1988, Models of tumour regression in endocrine related cancer, Vol. 1, 1 Beck, 1989, Oestrogen and the human breast, 95B, 1 Dickson, 1990, Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids, J Steroid Biochem Mol Biol, 37, 305, 10.1016/0960-0760(90)90479-5 Miller, 1987, Fundamental research leading to improved endocrine therapy for breast cancer, J Steroid Biochem, 27, 477, 10.1016/0022-4731(87)90343-8 Miller, 1990, Endocrine treatment for breast cancers: biological rationale and current progress, J Steroid Biochem Mol Biol, 37, 467, 10.1016/0960-0760(90)90390-7 Beatson, 1896, On the treatment of inoperable cases of carcinoma of the mammary. Suggestions for a new method of treatment with illustrative cases, Lancet, ii, 104, 10.1016/S0140-6736(01)72307-0 Leake, 1987, The molecular endocrinology of steroid hormones and their relation to cancer cell proliferation, 38 Laron, 1989, Clinical evidence on the role of oestrogens in the development of the breasts, 95B, 13 Anderson, 1989, The involvement of oestrogen in the development and function of the normal breast: histological evidence, 95B, 23 Vessey, 1989, The involvement of oestrogen in the development and progression of breast disease: epidemiological evidence, 95B, 35 Howell, 1989, Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer, 95B, 49 Bulbrook, 1989, Oestrogen in the initiation and promotion of breast cancer, 95B, 67 McGuire, 1975, Oestrogen receptors in human breast cancer: an overview, 1 McGuire, 1977, Steroid receptors in breast tumours: current status, Curr Topics Exp Endocrinol, 3, 93, 10.1016/B978-0-12-153203-1.50010-9 McGuire, 1977, Current status of oestrogen and progesterone receptors in breast cancer, Cancer, 39, 2934, 10.1002/1097-0142(197706)39:6<2934::AID-CNCR2820390680>3.0.CO;2-P McGuire, 1980, Steroid hormones in breast cancer treatment strategy, 135 Edwards, 1979, Oestrogen and progesterone receptor proteins in breast cancer, Biochem Biophys Acta, 560, 457 Lippman, 1976, The effects of oestrogens and antioestrogens on hormone responsive human breast cancer in long-term tissue culture, Cancer Res, 36, 4595 King, 1984, Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells, Nature, 307, 745, 10.1038/307745a0 Welshons, 1984, Nuclear localization of unoccupied oestrogen receptors, Nature, 307, 747, 10.1038/307747a0 Green, 1988, Nuclear receptors enhance our understanding of transcription regulation, Trends Genet, 4, 309, 10.1016/0168-9525(88)90108-4 Evans, 1988, The steroid and thyroid hormone receptor superfamily, Science, 240, 889, 10.1126/science.3283939 O'Malley, 1991, Molecular mechanism of action of a steroid hormone receptor, Rec Prog Hormone Res, 47, 1 Klein-Hitpass, 1986, An oestrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene function in transfected human cells, Cell, 46, 1053, 10.1016/0092-8674(86)90705-1 Seiler-tuyns, 1986, Identification of oestrogen-responsive DNA sequences by transient expression experiments in a human breast cancer cell line, Nucl Acids Res, 14, 8755, 10.1093/nar/14.22.8755 Elliston, 1990, Superactive oestrogen receptors, J Biol Chem, 265, 11517, 10.1016/S0021-9258(19)38427-3 Brown, 1990, Human oestrogen receptor forms multiple protein-DNA complexes, J Biol Chem, 265, 11238, 10.1016/S0021-9258(19)38582-5 Walter, 1985, Cloning of the human oestrogen receptor cDNA, 82, 7889 Green, 1986, Cloning of the human oestrogen receptor cDNA, J Steroid Biochem, 24, 77, 10.1016/0022-4731(86)90035-X Green, 1986, Human oestrogen receptor cDNA; sequence expression and homology to v-erbA, Nature, 320, 134, 10.1038/320134a0 Krust, 1986, The chickhen oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptor, EMBO J, 5, 891, 10.1002/j.1460-2075.1986.tb04300.x Ponglikitmongkol, 1988, Genomic organization of the human oestrogen receptor gene, EMBO J, 7, 3385, 10.1002/j.1460-2075.1988.tb03211.x Green, 1990, Modulation of oestrogen receptor activity by oestrogen and antioestrogens, J Steroid Biochem Mol Biol, 37, 747, 10.1016/0960-0760(90)90415-H Miller, 1985, Characterization of the subunit nature of nuclear oestrogen receptor by chemical cross-linking and dense amino acid labelling, Endocrinology, 117, 515, 10.1210/endo-117-2-515 Kumar, 1988, The oestrogen receptor binds tightly to its responsive elements as a ligand induced homodimer, Cell, 55, 145, 10.1016/0092-8674(88)90017-7 Fawell, 1990, Characterization and co-localization of steroid binding and dimerization activites in the mouse oestrogen receptor, Cell, 60, 953, 10.1016/0092-8674(90)90343-D Landschulz, 1988, The leucine zipper: a hypothetical structure common to a new class of DNA binding protein, Science, 240, 1759, 10.1126/science.3289117 Joab, 1984, Common non binding components in non-transformed chick oviduct receptors of four steroid hormones, Nature, 308, 850, 10.1038/308850a0 Schuh, 1985, A 90 000 dalton binding protein common to both steroid receptors and the Rous sacrcoma virus transforming protein pp60′-src, J Biol Chem, 260, 14292, 10.1016/S0021-9258(17)38716-1 Catelli, 1985, The common 90-KD protein component to non-transformed ‘8S’ steroid receptors is a heat shock protein, EMBO J, 4, 3131, 10.1002/j.1460-2075.1985.tb04055.x Chaumbraud, 1990, The formation of oestrogen receptor-hsp90 complexes involves several sites of interaction, J Biol Chem, 265, 20686 Bailly, 1986, Sequence-specific DNA binding of the progesterone receptor to the uteroglobin gene: effects of hormone, antihormone and receptor phosphorylation, EMBO J, 1986, 3235, 10.1002/j.1460-2075.1986.tb04634.x Denis, 1988, Requirement of hormone for thermal conversion of the glucocorticoid receptor to a DNA-binding state, Nature, 233, 686, 10.1038/333686a0 Kumar, 1987, Functional domains of the human oestrogen receptor, Cell, 51, 941, 10.1016/0092-8674(87)90581-2 Metzger, 1988, The human oestrogen receptor functions in yeast, Nature, 334, 31, 10.1038/334031a0 White, 1988, Experssion and function of the human oestrogen receptor in yeast, LIII, 819 Webster, 1988, The hormone binding domains of the oestrogen and glucocorticoid receptor contain an inducible transcription activation function, Cell, 54, 199, 10.1016/0092-8674(88)90552-1 Waterman, 1988, A single domain of the oestrogen receptor confers deoxyribonucleic acid binding and transcriptional activation of the rat prolactin gene, Mol Endocrinol, 2, 14, 10.1210/mend-2-1-14 Tora, 1989, The human receptor has two independent nonacidic transcriptional activation functions, Cell, 59, 477, 10.1016/0092-8674(89)90031-7 Lees, 1989, Identification of two trans-activation domains in the mouse oestrogen receptor, Nucl Acids Res, 17, 5477, 10.1093/nar/17.14.5477 Bocquel, 1989, The contribution of the N- and C- terminal regions of the steroid receptors to activation of transcription is both receptor and cell-specific, Nucl Acids Res, 17, 2581, 10.1093/nar/17.7.2581 Wakeling, 1988, Biology and mode of action of pure antioestrogens, J Steroid Biochem, 30, 141, 10.1016/0022-4731(88)90086-6 Wakeling, 1988, Novel antioestrogens without partial agonist activity, J Steroid Biochem, 31, 645, 10.1016/0022-4731(88)90014-3 Ruh, 1990, Differences in the form of the salt-transformed oestrogen receptor when bound by oestrogen versus antioestrogen, J Steroid Biochem, 36, 509, 10.1016/0022-4731(90)90166-P Wilson, 1990, Comparative study of the interaction of oestrodiol and the pure antioestrogen ICI 164 384, with the molydate-stabilized oestrogen receptor, J Steroid Biochem, 35, 421, 10.1016/0022-4731(90)90250-V Berry, 1990, Role of the two activating domains of the oestrogen receptor in the cell-type and promotercontext dependent agonist activity of the anti-oestrogen 4-hydroxytamoxifen, EMBO J, 9, 2811, 10.1002/j.1460-2075.1990.tb07469.x Fauque, 1985, A monoclonal antibody to the oestrogen receptor inhibits In vitro: criteria of receptor activation by an oestrogen and an antioestrogen, J Biol Chem, 260, 15547, 10.1016/S0021-9258(17)36291-9 Ojasoo, 1993, Breast cancer: When tumour markers become targets for drugs, Ann Oncol, 4, 195, 10.1093/oxfordjournals.annonc.a058455 Hollenberg, 1987, Colocalization of DNA-binding and transcriptional activation functions in the human glucocorticoid receptor, Cell, 49, 39, 10.1016/0092-8674(87)90753-7 Jordan, 1984, Biochemical Pharmacology of antioestrogen action, Pharmacol Rev, 36, 245 May, 1987, Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 oestrogen regulated RNAs in human breast cancer cells, J Biol Chem, 262, 15894, 10.1016/S0021-9258(18)47673-9 Nunez, 1989, The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein, EMBO J, 8, 823, 10.1002/j.1460-2075.1989.tb03443.x Jordan, 1986 Furr, 1984, The pharmacology and clinical uses of tamoxifen, Pharmacol Ther, 25, 127, 10.1016/0163-7258(84)90043-3 Winstanley, 1991, The long term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast, Br J Cancer, 64, 99, 10.1038/bjc.1991.249 Dodds, 1938, Oestrogenic activity of certain synthetic compounds, Nature, 141, 247, 10.1038/141247b0 Dodds, 1938, Biological effects of the synthetic oestrogenic substance 4:4′-dihydroxy-alpha: beta-diethylstilbene, Lancet, i, 1389, 10.1016/S0140-6736(00)89468-4 Lerner, 1958, A non-steroidal oestrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methyoxyphenyl ethanol, Endocrinology, 63, 295, 10.1210/endo-63-3-295 Lerner, 1981, The first non-steroidal antioestrogen MER 25, 1 Segal, 1958, An orally active compound with antifertility effects in rats, 98, 431 Chang, 1959, Degeneration of ova in the rat and rabbit following oral administration of 1-(p-2-diethyl aminoethoxyphenyl)-1-phenyl-2-p-anisylethenol, Endocrinology, 65, 339, 10.1210/endo-65-2-339 Smith, 1963, Action of MER-25 and of clomiphene on the human ovary, J Am Med Assoc, 184, 122, 10.1001/jama.1963.73700240008012 Lerner, 1990, Development of antioestrogens and their use in breast cancer: eighth Cain memorial award lecture, Cancer Res, 50, 4177 Holtkamp, 1960, Gonadotrophin inhibiting and anti-fecundity effects of chloramiphene, 105, 197 Emmens, 1970, Postcoital contraception, Br Med Bull, 26, 45, 10.1093/oxfordjournals.bmb.a070742 Emmens, 1971, Compounds exhibiting prolonged antioestrogenic and antifertility activity in mice and rats, J Reprod Fertil, 26, 175, 10.1530/jrf.0.0260175 Emmens, 1973, Further studies of compounds exhibiting prolonged antioestrogenic and antifertility activity in the mouse, J Reprod Fertil, 34, 29, 10.1530/jrf.0.0340029 Bishop, 1970, Clomiphene, Br Med Bull, 26, 22, 10.1093/oxfordjournals.bmb.a070737 Greenblatt, 1961, Induction of ovulation with MRL41, J Am Med Assoc, 178, 101, 10.1001/jama.1961.03040410001001 Greenblatt, 1962, Induction of ovulation, Am J Obstet Gynecol, 84, 900, 10.1016/0002-9378(62)90067-4 Clark, 1977, Clomid or nafoxidine administered to neonatal rats causes reproductive tract abnormalities, Science, 197, 164, 10.1126/science.877546 Clark, 1982, The agonistic-antagonistic properties of clomiphene: a review, Pharmacol Ther, 15, 467, 10.1016/0163-7258(81)90055-3 Ruenitz, 1982, Oestrogenic and antioestrogenic activity of momophenolic analogues of tamoxifen (Z)-2-[p-(1,2-diphenyl-1-butenyl) phenoxy]-N,N-dimethylethylamine, J Med Chem, 25, 1056, 10.1021/jm00351a010 Huppert, 1979, Induction of ovulation with clomiphene citrate, Fertil Steril, 31, 1, 10.1016/S0015-0282(16)43749-0 Harper, 1967, Mode of action of I.C.I. 46,474 in preventing implantation in rats, J Endocrinol, 37, 83, 10.1677/joe.0.0370083 Harper, 1967, A new derivative of triphenylethylene: effect on implantation and mode of action in rats, J Reprot Fertil, 13, 101, 10.1530/jrf.0.0130101 Pasqualini, 1988, Pharmacodynamic and biological effects of antioestrogens in different models, J Steroid Biochem, 31, 613, 10.1016/0022-4731(88)90013-1 Wakeling, 1984, Nonsteroidal antioestrogens receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells, J Steroid Biochem, 20, 111, 10.1016/0022-4731(84)90197-3 Miquel, 1988, A chemical classification of nonsteroidal antagonists of sex-steroid hormone action, J Steroid Biochem, 31, 525, 10.1016/0022-4731(88)90004-0 Leclercq, 1979, Physiological and pharmacological effects of oestrogens in breast cancer, Biochem Biophys Acta, 560, 427 Paridaen, 1983, Steroid hormones, analogues and antagonists, 171 Jordan, 1984, Structural requirements for the pharmacological activity of nonsteroidal antioestrogens in vitro, Mol Pharmacol, 26, 272 Pavlik, 1980, The stability of the uterine oestrogen receptor when complexed with oestrogen or antioestrogens, Mol Pharmacol, 18, 406 Lyman, 1985, Possible mechanism for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus, Biochem. Pharmacol., 34, 2795, 10.1016/0006-2952(85)90581-7 Kallio, 1986, A new triphenylethylene compound, Fc-1157a; I: Hormonal effects, Cancer Chemother Pharmacol, 17, 103, 10.1007/BF00306736 Jordan, 1982, Importance of the alkylaminoethoxy sidechain for the oestrogenic and antioestrogenic actions of tamoxifen and trioxifene in the immature rat uterus, Mol Cell Endocrinol, 27, 291, 10.1016/0303-7207(82)90095-8 Robertson, 1982, Antioestrogen basicity-activity relationships: a comparison of the oestrogen receptor binding and antiuterotrophic potencies of several analogues of tamoxifen (Nolvadex) having altered basicity, J Med Chem, 25, 167, 10.1021/jm00344a015 Black, 1983, Antagonium of oestrogen action with new benzothiophene derived antioestrogen, Life Sci, 32, 1031, 10.1016/0024-3205(83)90935-9 Leclercq, 1984, In vitro testing of cytotoxic compounds in hormone dependent and independent breast cancer cell lines, Can Treat Rev, 11, 163, 10.1016/0305-7372(84)90056-2 Wakeling, 1991, A potent specific pure antioestrogen with clinical potential, Cancer Res, 51, 3867 Cole, 1971, A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 146 474, Br J Cancer, 25, 270, 10.1038/bjc.1971.33 Jordan, 1988, Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trials, 105 Jordan, 1989, Optimisation of antioestrogen therapy: Laboratory and clinical concepts, 95B, 239 Stewart, 1989, Clinical experience in the use of the antioestrogen tamoxifen in the treatment of breast cancer, 95B, 231 Nolvadex Adjuvant Trial Organization, 1985, Controlled trail of tamoxifen as single adjuvant agent in the management of early breast cancer, Lancet, i, 836 Nolvadex Adjuvant Trial Organization, 1988, Controlled trial of tamoxifen as single adjuvant agent in the management of early breast cancer, Br J Cancer, 57, 608, 10.1038/bjc.1988.138 Scottish Breast Cancer Trials Committee, 1987, Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial, Lancet, ii, 171 Mouridsen, 1978, Tamoxifen in advanced breast cancer, Can Treat Rep, 5, 131, 10.1016/S0305-7372(78)80017-6 Goldhirsch, 1985, Adjuvant treatment in operable breast cancer, J Steroid Biochem, 23, 1155, 10.1016/0022-4731(85)90036-6 Jonat, 1987, The present status of the adjuvant endocrine treatment, J Steroid Biochem, 27, 499, 10.1016/0022-4731(87)90346-3 Castagnetta, 1985, Modulation of oestrogen excretion profiles by adjuvant chemotherapy in pre and postmenopausal breast cancer, J Steroid Biochem, 23, 1115, 10.1016/0022-4731(85)90029-9 Smith, 1988, Adjuvant tamoxifen for early breast cancer, Br J Cancer, 57, 527, 10.1038/bjc.1988.122 1988, Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among women, N Engl J Med, 319, 1681, 10.1056/NEJM198812293192601 Nicholson, 1986, Antioestrogens and breast cancer therapy, 60 Jordan, 1980, Pharmacology of tamoxifen in laboratory animals, Can Treat Rep, 64, 745 Coezy, 1982, Tamoxifen and metabolites in MCF-7 cells: Correlation between binding to oestrogen receptor and inhibition of cell growth, Cancer Res, 42, 317 Bardon, 1984, The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the oestrogen receptor, Mol Cell Endrocrinol, 35, 89, 10.1016/0303-7207(84)90004-2 Gottardis, 1987, The antitumour actions of keoxifene and tamoxifen in the N-nitrosomethylurea induced rat mammary carcinoma model, Cancer Res, 47, 4020 Gottardis, 1989, Inhibition of tamoxifen stimulated growth of an MCF-7 tumour variant in athymic mice by novel steroidal antioestrogen, Cancer Res, 49, 4090 Wilkinson, 1986, Response of nitrosomethylurea-induced rat mammary tumour to endocrine therapy and comparison with clinical response, Cancer Res, 46, 4862 Gottardis, 1988, Oestradiol stimulated growth of MCF-7 tumours implanted in athymic mice: a model to study the tumouristatic action of tamoxifen, J Steroid Biochem, 30, 311, 10.1016/0022-4731(88)90113-6 Osborne, 1983, Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase, Cancer Res, 43, 3583 Sutherland, 1983, Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells, Cancer Res, 43, 3998 Taylor, 1983, Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells, Cancer Res, 43, 4007 Musgrove, 1989, Points of action of oestrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle, Cancer Res, 49, 2398 Jordan, 1983, Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antioestrogens: problems and potential for future clinical applications, Breast Can Res Treat, 3, 73, 10.1007/BF01855131 Wolmark, 1989, A comparison of two and three years of adjuvant tamoxifen, Horm Res, 32, 166, 10.1159/000181337 Jackson, 1987, Clinical uses of antioestrogens, 87 Litherland, 1988, Antioestrogen in the management of hormone dependent cancer, Cancer Treat Rev, 15, 183, 10.1016/0305-7372(88)90002-3 Baum, 1989, Current controversies in the role of antioestrogens in the treatment of carcinoma of the breast, 95B, 221 Dickson, 1987, Oestrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma, Endocrine Rev, 8, 29, 10.1210/edrv-8-1-29 Lippman, 1989, Growth control of normal and malignant epithelium, 95B, 89 Lippman, 1989, Mechanisms of growth control in normal and malignant breast epithelium, Rec Prog Horm Res, 45, 383 Dickson, 1990, Stimulatory and inhibitory growth factors and breast cancer, J Steroid Biochem Mol Biol, 37, 795, 10.1016/0960-0760(90)90422-H Sporn, 1985, Autocrine growth factors and cancer, Nature, 313, 745, 10.1038/313745a0 Bronzert, 1986, Oestrogen and antioestrogen resistance in human breast, Adv Exp Med Biol, 196, 329, 10.1007/978-1-4684-5101-6_22 Knabbe, 1987, Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells, Cell, 48, 417, 10.1016/0092-8674(87)90193-0 Green, 1986, A superfamily of potentially oncogenic hormone receptors, Nature, 324, 615, 10.1038/324615a0 Murphy, 1990, Oestrogen receptor variants in human breast cancer, Mol Cell Endocrinol, 74, c83, 10.1016/0303-7207(90)90109-L Reese, 1991, Mutagenesis of cysteines in the hormone binding domain of the human oestrogen receptor, J Biol Chem, 266, 10880, 10.1016/S0021-9258(18)99101-5 Katzenellenbogen, 1991, Antioestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy, J Natl Cancer Inst, 83, 1434, 10.1093/jnci/83.20.1434 Parmar, 1988, Oestrogen receptor activation and molecular forms in human breast cancer, J Steroid Biochem, 31, 359, 10.1016/0022-4731(88)90302-0 Scott, 1991, Truncated forms of DNA-binding oestrogen receptor in human breast cancer, J Clin Invest, 88, 700, 10.1172/JCI115356 Klinge, 1992, Cooperative oestrogen receptor interaction with consensus or variant oestrogen responsive elements In vitro, Cancer Res, 52, 1073 Fuqua, 1991, Variant human breast tumour oestrogen receptor with constitutive transcriptional activity, Cancer Res, 51, 105 Fuqua, 1992, Inhibition of oestrogen receptor action by a naturally occurring variant in human breast tumours, Cancer Res, 52, 483 Sorrentio, 1989, Growth factor growth inhibitors and cell cycle control (Review), Anticancer Res, 9, 1925 Travers, 1988, Growth factor transcripts in normal benign and malignant breast tissue, Br Med J, 296, 1621, 10.1136/bmj.296.6637.1621 Bates, 1988, Expression of TGF-alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance, Endocrinology, 2, 543 Dickson, 1992, Regulation of tumour-host interactions in breast cancer, J Steroid Biochem Mol Biol, 41, 389, 10.1016/0960-0760(92)90364-O Wakeling, 1990, Mechanism of growth regulation of human breast cancer, 51 Bronzert, 1990, Transforming growth factor-beta induces platelet-derived growth factor (PDGF) messenger RNA and PDGF secretion while inhibiting growth in normal human mammary epithelial cells, Mol Endocrinol, 4, 981, 10.1210/mend-4-7-981 Bronzert, 1987, Synthesis and secretion of PDGF-like growth factor by human breast cancer cell lines, 84, 5763 Valverius, 1989, Production and responsiveness to TGF-beta in normal and oncogene transformed human mammary epithelial cells, Cancer Res, 49, 6269 Sporn, 1988, Transforming growth factor-beta, Adv Cancer Res, 51, 107, 10.1016/S0065-230X(08)60221-3 Robers, 1986, Transforming growth factor-beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation In vitro, 83, 4167 Robert, 1989, The Transforming growth factor beta Arteaga, 1988, Transforming growth factor beta: potential autocrine growth inhibitor of oestrogen receptor-negative human breast cancer cells, Cancer Res, 48, 3898 Colletta, 1990, Antioestrogens induced the secretion of active TGF-beta from human fetal fibroblast, Br J Cancer, 62, 405, 10.1038/bjc.1990.307 Silberstein, 1987, Reversible inhibition of mammary gland growth by TGF-beta, Science, 237, 291, 10.1126/science.3474783 Zugmaier, 1991, Transforming growth factor beta I induces cachexia and systemic fibrosis without an antitumour effect in nude mice, Cancer Res, 51, 3590 Li, 1991, Expression of multiple species of basic fibroblast growth factor mRNA and protein in normal and tumour-derived mammary epithelial cells in culture, Cell Growth Diff, 2, 195 Luqmani, 1992, Expression of basic FGF, FGFR1 and FGFR2 in normal and malignant human breast and comparison with other normal tissues, Br J Cancer, 66, 273, 10.1038/bjc.1992.256 Gomm, 1991, Localization of basic fibroblast growth factor and TGF-beta-1 in the human mammary gland, Cancer Res, 51, 4685 Gaffney, 1986, Lymphocyte activating and growth inhibitory activities for several sources of native and recombiant interleukin 1, Cancer Res, 46, 3834 Paciotti, 1988, Interleukin-I directly regulates hormone dependent human breast cancer cell proliferation in vitro, Mol Endocrinol, 2, 459, 10.1210/mend-2-5-459 Reed, 1992, Interleukin-1 and 6 in breast cancer cyst fluid: their role in regulating aromatase in breast cancer cells, J Endocrinol, 132, 125, 10.1677/joe.0.132R005 Danforth, 1991, Interleukin 1-alpha blocks oestradiol stimulated growth and down regulates the oestrogen receptor in MCF-7 breast cancer cells, Cancer Res, 51, 1488 Robinson, 1992, IL-2 in breast cyst fluid and secretion by T47-D breast cancer cells, J Endocrinol, 132, 272 Toi, 1992, Inhibition of colon and breast carcinoma cell growth by IL-4, Cancer Res, 52, 275 Jordan, 1987, Strategies for breast cancer therapy with antioestrogens, J Steroid Biochem, 27, 493, 10.1016/0022-4731(87)90345-1 Sutherland, 1981 Tormey, 1976, Evaluation of tamoxifen dose in advanced breast cancer: a progress report, Cancer Treat Rep, 60, 1451 McIntosh, 1979, Tumour stimulation by antioestrogens, Br J Surg, 64, 900, 10.1002/bjs.1800641218 Plotkin, 1978, Tamoxifen flare in advanced breast cancer, J Am Med Assoc, 240, 2644, 10.1001/jama.240.24.2644 Smith, 1981, Tamoxifen verus aminoglutethimide in advanced breast cancer carcinoma: a randomized cross-over trial, Br Med J, 283, 1432, 10.1136/bmj.283.6304.1432 Murray, 1982, Aminoglutethimide in tamoxifen-resistant patients: the Melbourne experience, Cancer Res, 42, 3437s Buzdar, 1982, Aminoglutethimide after tamoxifen therapy in advanced breast cancer: MD Anderson Hospital Experience, Cancer Res, 42, 3448s Callantine, 1966, Action of an oestrogen antagonist on reproductive mechanism in the rat, Endocrinology, 79, 153, 10.1210/endo-79-1-153 Callantine, 1967, Non-steroidal oestrogen antagonists, Clin Obstet Gynaecol, 10, 74, 10.1097/00003081-196703000-00007 Ruenitz, 1989, Characterization of MCF-7 breast cancer cell growth inhibition by the antioestrogen nitromifene (CI 628) and selected metabolites, J Steroid Biochem, 33, 365, 10.1016/0022-4731(89)90325-7 Valavaara, 1988, Toremifene, A new antioestrogenic compound, for treatment of advanced breast cancer. Phase II study, Eur J Cancer Clin Oncol, 24, 785, 10.1016/0277-5379(88)90316-1 Kangas, 1990, Proceeding of the toremifene symposium, 36, 187 Jones, 1979, Synthesis and antioestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl]-[4-[2-(1-pyrrolidinyl) ethoxy] phenyl]methanone, methsulfonic acid salt, J Med Chem, 22, 962, 10.1021/jm00194a015 Rose, 1981, Activity of the antioestrogen trioxifene against N-nitrosomethylurea induced rat mammary carcinomas, Eur J Clin Oncol, 17, 893, 10.1016/0014-2964(81)90311-X Witte, 1986, A phase III investigation of trioxifene mesylate in advanced breast cancer: Clinical and endocrinologic effects, Cancer, 57, 34, 10.1002/1097-0142(19860101)57:1<34::AID-CNCR2820570109>3.0.CO;2-W Lee, 1986, Trioxifene mesylate in the treatment of breast cancer, Cancer, 57, 40, 10.1002/1097-0142(19860101)57:1<40::AID-CNCR2820570110>3.0.CO;2-W Schneider, 1986, 2-Alkyl-substituted 1,1-bis(4-acetoxyphenyl)-2-phenylethenes. Oestrogen receptor affinity, oestrogenic and antioestrogenic properties and mammary tumour inhibiting activity, J Med Chem, 29, 1494, 10.1021/jm00158a029 Schneider, 1986, Acetoxy substituted 1,1,2-triphenyl-1-enes: oestrogenic, antioestrogenic and mammary tumour inhibiting activity, J Cancer Res Clin Oncol, 112, 119, 10.1007/BF00404393 Schneider, 1986, Catechol oestrogens of the 1,1,2-triphenylbut-1-ene type: relationship between structure, oestradiol receptor affinity, oestrogenic and antioestrogenic properties and mammary tumour inhibiting activites, J Med Chem, 29, 1355, 10.1021/jm00158a006 Schneider, 1986, 2-Phenylindenes: development of a new mammary tumour inhibiting antioestrogen by combination of oestrogenic side effect lowering structural elements, J Med Chem, 29, 75, 10.1021/jm00151a012 von Angerer, 1984, Development of new drugs for endocrine tumour chemotherapy, Cancer Treat Rev, II, 147, 10.1016/0305-7372(84)90054-9 von Angerer, 1985, The inhibitory effect of actoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (DI-6726) on oestrogen-dependent mammary tumours, Eur J Cancer Clin Oncol, 21, 531, 10.1016/0277-5379(85)90048-3 Hilgard, 1988, Comparative pharmacology of zindoxifene and tamoxifen, 369 Stein, 1990, Phase III study of the antioestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A cancer Research Campaign Phase III Clinical Trials Committee study, Br J Cancer, 61, 431, 10.1038/bjc.1990.99 Robinson, 1988, In vitro oestrogenic action in rat and human cells of hydroxylated derivatives of D 16726 (zindoxifene), an agent with known anti-mammary cancer activity in vivo, Cancer Res, 48, 784 Kangas, 1986, A new triphenylethylene compound Fc-1157a. II: Antitumour effects, Cancer Chemother Pharmacol, 17, 109, 10.1007/BF00306737 Robinson, 1988, Antitumour actions of toremifene in the 7,12-Dimethylbenzanthracene (DMBA)-induced rat mammary tumour model, Eur J Cancer Clin Oncol, 24, 1817, 10.1016/0277-5379(88)90091-0 Kangas, 1989, Biodistribution and Scintigraphy of 11-C-Toremifene in rats bearing DMBA induced mammary carcinoma, Pharmacol Toxicol, 64, 373, 10.1111/j.1600-0773.1989.tb00668.x DiSalle, 1990, Antioestrogenic and antitumour properties of the new triphenylethylene derivative toremifene in the rat, J Steroid Biochem, 36, 203, 10.1016/0022-4731(90)90005-D Duncan, 1963, Antifertility activties of two diphenyl-dihydronaphalene derivatives, 112, 439 Clark, 1979, Female sex steroids, 14, 118 Terenius, 1971, Structure-activity relationships of antioestrogens with regard to interaction with 17-beta oestradiol in the mouse uterus and vagina, Acta Endocrinol, 66, 431, 10.1530/acta.0.0660431 Terenius, 1971, Anti-oestrogens and breast cancer, Eur J Cancer, 7, 57, 10.1016/0014-2964(71)90095-8 Terenius, 1971, Effect of antioestrogens on initiation of mammary cancer in the female rat, Eur J Cancer, 7, 65, 10.1016/0014-2964(71)90096-X Gulino, 1980, Specific binding and biological response of antioestrogens in the fetal uterus of the guinea pig, Cancer Res, 40, 3821 Heuson, 1972, Clinical trial of nafoxidine, an oestrogen antagonist in advanced breast cancer, Eur J Cancer, 8, 387, 10.1016/0014-2964(72)90121-1 Bloom, 1974, Antioestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases, Br Med J, 2, 7, 10.1136/bmj.2.5909.7 Jordan, 1977, A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity, Endocrinology, 75, 305, 10.1677/joe.0.0750305 Wakeling, 1980, Oestrogen receptor binding and biologic activity of tamoxifen and its metabolites, Cancer Treat Rep, 64, 741 Roos, 1983, Antioestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7, J Natl Cancer Inst, 71, 55 Loser, 1985, In vivo and in vitro antioestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen, Eur J Cancer Clin Oncol, 21, 985, 10.1016/0277-5379(85)90119-1 Dietel, 1989, Effect of continuous vs. intermittent application of 3-OH-tamoxifen or tamoxifen on the proliferation of the human breast cancer cell line MCF-7 1, J Cancer Res Clin Oncol, 115, 36, 10.1007/BF00391597 Black, 1980, Uterine bioassay of tamoxifen, trioxifene and a new oestrogen antagonist (LY117018) in rats and mice, Life Sci, 26, 1453, 10.1016/0024-3205(80)90049-1 Black, 1981, Evidence for the biological action of the antioestrogens LY117018 and tamoxifen by different mechanisms, Endocrinology, 109, 987, 10.1210/endo-109-3-987 Jordan, 1983, Inhibition of the uterotrophic activity of oestrogens by the short acting antioestrogen LY117018, Endocrinology, 113, 463, 10.1210/endo-113-2-463 Wakeling, 1983, Comparison of the biological effects of tamoxifen and a new antioestrogen (LY117018) on the immature rat uterus, J Endocrinol, 99, 447, 10.1677/joe.0.0990447 Wakeling, 1983, Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens, J Endocrinol, 99, 455, 10.1677/joe.0.0990455 Campen, 1985, Opposing biological actions of antioestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus, Endocrinology, 116, 2327, 10.1210/endo-116-6-2327 Jones, 1984, Antioestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-aryl benzo[b]thiophene derivatives leading to LY156758, a remarkably effective oestrogen antagonist with only minimal intrinsic oestrogenicity, J Med Chem, 27, 1057, 10.1021/jm00374a021 Clemens, 1983, Effect of a new antioestrogen, Keoxfene (LY156758), on the growth of carcinogen-induced mammary tumours and on LH and prolactin levels, Life Sci, 32, 2869, 10.1016/0024-3205(83)90323-5 Gallick, 1983, Disposition and metabolism of a new antioestrogen LY156758, in rats, dogs and monkeys, 42, 376 Jordan, 1983, Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer, Cancer Res, 43, 1446 Katzenellenbogen, 1982, Considerations in the design and evaluation of cytotoxic oestrogens, Breast Can Res Treat, 2, 347, 10.1007/BF01805876 Katzenellenbogen, 1986, Cytotoxic oestrogens and antioestrogens: concepts, progress and evaluation, 41 Raus, 1980 Leclercq, 1983, Guidelines in the design of new antioestrogens and cytotoxic-linked oestrogens for the treatment of breast cancer, J Steroid Biochem, 19, 75, 10.1016/S0022-4731(83)80009-0 Allegra, 1979, Distribution, frequency and quantitative analysis of oestrogen, progesterone, androgen and glucocorticoid receptors in human breast cancer, Cancer Res, 39, 1447 Wall, 1969, The effects of some steroidal alkylating agents on experimental animal mammary tumour and leukemia systems, J Med Chem, 12, 810, 10.1021/jm00305a021 Schonemann, 1980, Potential antitumour agents: 11-beta-(1-aziridinyl methyl) derivatives of oestradiol and oestrone, Eur J Med Chem, 15, 333 Lam, 1979, Synthesis of steroidal nitrosoureas with antitumour activity, J Med Chem, 22, 200, 10.1021/jm00188a015 Hamacher, 1980, N-mustard groups linked to oestrogens: problems of synthesis and receptor affinity, 107 Jordan, 1981, Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens, Eur J Cancer, 17, 193, 10.1016/0014-2964(81)90036-0 Leclercq, 1980, In vitro screening for cytotoxic oestrotens of potential therapeutic activity, 165 Sanberg, 1980, The fate and biochemical effects of estracyt in the human and baboon, 219 Forsgren, 1980, 245 Leclercq, 1976, Affinity of oestradiol mustard for oestrogen receptors and its enzymatic degradation in uterine and breast cancer cytosols, Int J Cancer, 18, 750, 10.1002/ijc.2910180605 Leclercq, 1985, In vitro synergism between oestrogens and cytotoxic agents, J Steroid Biochem, 23, 1111, 10.1016/0022-4731(85)90028-7 Leckercq, 1976, Oestrogen receptors interaction with estracyt and degradation products, a biochemical study on a potential agent in the treatment of breast cancer, Eur J Drug Metab Pharmacokinet, 2, 77, 10.1007/BF03189261 Alexander, 1979, Estracyt in advanced carcinoma of the breast: a phase II study, Clin Radiol, 30, 139, 10.1016/S0009-9260(79)80133-6 Jonsson, 1977, Treatment of advanced prostatic carcinoma with estramustine phosphate (estracyt), Scand J Urol Nephrol, 11, 231, 10.3109/00365597709179957 Hartley-Asp, 1982, Growth and cell survival following treatment with estramustine, nor-nitrogen mustard, oestradiol and testosterone of a human prostatic cancer cell line (DU 145), J Urol, 127, 818, 10.1016/S0022-5347(17)54057-4 Dawes, 1982, A pilot study of estracyt in advanced breast cancer, Cancer Treat Rep, 66, 581 Wakeling, 1990, Therapeutic potential of pure antioestrogens in the treatment of breast cancer, J Steroid Biochem Mol Biol, 37, 771, 10.1016/0960-0760(90)90418-K Poulin, 1989, Antioestrogenic properties of keoxifene, trans-4-hydroxytamoxifen and ICI 164 384, a new steroidal antioestrogen, in ZR-75-1 human breast cancer cells, Breast Can Res Treat, 14, 65, 10.1007/BF01805977 Thompson, 1989, ICI 164 384, a pure antagonist of oestrogen stimulated MCF-7 cell proliferation and invasiveness, Cancer Res, 49, 6929 Chander, 1991, Coombes RC. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antioestrogen tamoxifen for the treatment of breast cancer, Cancer Res, 51, 5851 Jarman, 1986, Analogues of tamoxifen: the role of the basic side-chain. Application of a whole cell oestrogen receptor binding assay to N-oxides and quaternary salts, Anti-Cancer Drug Design, 1, 259 McCague, 1986, Halogenated Tamoxifen McCague, 1989, Derivatives of tamoxifen. Dependence of antioestrogenity on the 4-substituent, J Med Chem, 32, 2527, 10.1021/jm00132a006 Jordan, 1980, Evaluation of the antitumour activity of the nonsteroidal antioestrogen, mono hydroxy-tamoxifen, in the DMBA induced rat mammary carcinoma model, Eur J Cancer, 16, 239, 10.1016/0014-2964(80)90156-5 Foster, 1986, Modification of the basic side chain in tamoxifen: effects on microsomal metabolism and in vitro biological activity, Anti-Cancer Drug Design, 1, 245 McCague, 1990, Metabolism of tamoxifen by isolated rat heptocytes. Identification of the glucuronide of 4-hydroxy-tamoxifen, Biochem Pharmacol, 39, 1459, 10.1016/0006-2952(90)90427-M Ohkubo, 1990, Multiplicity of in vivo glucuronidation of 2-hydroxyoestradiol, J Steroid Biochem, 36, 501, 10.1016/0022-4731(90)90094-9 Jordan, 1988, Ligand interaction at the oestrogen receptor to program antioestrogen action: a study with nonsteroidal compounds in vitro, Endocrinology, 122, 1449, 10.1210/endo-122-4-1449 Jordan, 1990, Endocrine Pharmacology of antioestrogens as antitumour agents, Endocrine Rev, 11, 578, 10.1210/edrv-11-4-578 Allen, 1980, Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structureactivity relationship, Br J Pharmacol, 71, 83, 10.1111/j.1476-5381.1980.tb10912.x McNab, 1984, An evaluation of tamoxifen as a partial agonist by classical receptor theory — an explanation of the dual action of tamoxifen, Eur J Pharmacol, 103, 321, 10.1016/0014-2999(84)90493-X Wakeling, 1986, Pharmacology of antioestrogens, 1 Bolt, 1979, Metabolism of oestrogens — natural and synthetic, Pharmacol Ther, 4, 155, 10.1016/0163-7258(79)90018-4 Lyman, 1985, Metabolism of tamoxifen and its uterotrophic activity, Biochem Pharmacol, 34, 2787, 10.1016/0006-2952(85)90580-5 Lyman, 1986, Metabolism of nonsteroidal antioestrogens, 191 Etienne, 1989, Tamoxifen metabolism: pharmacokinetics and in vitro study, Br J Cancer, 60, 30, 10.1038/bjc.1989.214 Lien, 1991, Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients, Br J Cancer, 63, 641, 10.1038/bjc.1991.147 Fromson, 1973, The metabolism of tamoxifen (ICI 46 474): Part I in laboratory animals, Xenobiotica, 3, 693, 10.3109/00498257309151594 Fromson, 1973, The metabolism of tamoxifen (ICI 46 474): part II in female patients, Xenobiotica, 3, 711, 10.3109/00498257309151595 Adams, 1979, The metabolism of tamoxifen in humans, Biochem Pharmacol, 27, 145, 10.1016/0006-2952(79)90283-1 Bain, 1983, Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy, Biochem Pharmacol, 32, 373, 10.1016/0006-2952(83)90571-3 Kemp, 1983, Identification and biological activity of tamoxifen metabolites in human sera, Biochem Pharmacol, 32, 2045, 10.1016/0006-2952(83)90425-2 Foster, 1980, Metabolism of tamoxifen by rat microsomes: formation of the N-oxide, a new metabolite, Biochem Pharmacol, 29, 1977, 10.1016/0006-2952(80)90116-1 Sutherland, 1979, Differential binding of antioestrogens by rat uterine and chick oviduct cytosol, Biochem Biophys Res Commun, 91, 183, 10.1016/0006-291X(79)90601-6 Ruenitz, 1985, Affinity of ligands other than triarylethylenes for liver microsomal antioestrogens binding sites, Biochem Pharmacol, 34, 2807, 10.1016/0006-2952(85)90582-9 Kida, 1989, Hormonal regulation of synthesis and secretion of pS2 protein relevant to growth of human breast cancer cells (MCF-7), Cancer Res, 49, 3494 Davidson, 1986, Use of two MCF-7 cell variants to evaluate the growth regulatory potential of oestrogen induced products, Cancer Res, 46, 1904 Skilton, 1989, Characterisation of a messenger RNA selectively expressed in human breast cancer, Br J Cancer, 60, 168, 10.1038/bjc.1989.245 Henry, 1989, Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy, Br J Cancer, 61, 32, 10.1038/bjc.1990.8 Johnson, 1989, Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells, Br J Cancer, 59, 727, 10.1038/bjc.1989.153 Schwartz, 1991, pS2 expression and response to hormonal therapy in patients with advanced breast cancer, Cancer Res, 51, 624 Luqmani, 1993, Prediction of response to endocrine therapy using immunocytochemical assays for oestrogen receptor, progesterone receptor and pS2, Int J Cancer, 54, 619, 10.1002/ijc.2910540416 Arrick, 1990, Differential regulation of expression of three transforming growth factor beta species in human cancer cell lines by oestradiol, Cancer Res, 50, 299 Barnard, 1990, The cell biology of transforming growth factor beta, Biochim Biophys Acta, 1032, 79 Freiss, 1990, Anti-steroidal and anti-growth factor activities of antioestrogens, J Steroid Biochem Mol Biol, 37, 777, 10.1016/0960-0760(90)90419-L Gong, 1922, Differential effects of oestrogen and antioestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells, Cancer Res, 52, 1704 Luqmani YA, Desai A, Coombes RC. Detection of estrogen receptor mRNA lacking exon 5 in human breast cancer: clinical Applications. Conference on ‘Mutant Oncogens: targets for therapy’. London. Powles, 1992, Chemoprevention of breast cancer — a randomised trial, Ann Oncol, 3, 60 Fendl, 1992, Role of tamoxifen in the induction of hormone-independent rat mammary tumours, Cancer Res, 52, 235 Daly, 1990, Cellular and molecular events in loss of oestrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells, Cancer Res, 50, 5868 Judson, 1989, New endocrine agents, guidelines for future development, Br J Cancer, 60, 153, 10.1038/bjc.1989.240 Rahman, 1989, Anti-laminin receptor antibody targeting: Liposomes with encapsulated doxorubicin in human breast cancer cells in vitro, J Natl Cancer Inst, 81, 1794, 10.1093/jnci/81.23.1794 Vitols, 1990, Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex, Br J Cancer, 62, 724, 10.1038/bjc.1990.367 Gabizon, 1991, Pharmacokinetics and imaging studies in patients receiving a formulation of liposome-associated Adriamycin, Br J Cancer, 64, 1125, 10.1038/bjc.1991.476 Goldberg, 1992, An in vivo assessment of Adriamycin-loaded albumin microspheres, Br J Cancer, 65, 393, 10.1038/bjc.1992.79 Kosano, 1992, Growth inhibitory action of an oestorgen-chlorambucil conjugate (KM2210) in human breast cancer cell line MCF-7: its relation to reduction of oestrogen receptor and transforming growth factor alpha secretion, Cancer Res, 52, 1187 Bagshawe, 1989, Towards generating cytotoxic agents at cancer sites, Br J Cancer, 60, 275, 10.1038/bjc.1989.270 Gospodarowicz, 1986, Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells, Cell Diff, 19, 1, 10.1016/0045-6039(86)90021-7 Moscatelli, 1986, Both normal and tumour cells produce basic fibroblast growth factor, J Cell Physiol, 129, 273, 10.1002/jcp.1041290220 Fernig, 1990, Appearance of basic fibroblast growth factor receptor upon differentiation of rat mammary epithelial to myoepithelial like cells in culture, J Cell Physiol, 142, 108, 10.1002/jcp.1041420114 Lappi, 1989, Biological and chemical characterization of bFGF-saporin, Biochem Biophys Res Commun, 160, 917, 10.1016/0006-291X(89)92522-9 Beitz, 1992, Antitumour activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo, Cancer Res, 52, 227